AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 149 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.35 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $14,017,000 | -25.8% | 499,000 | 0.0% | 0.46% | -19.3% |
| Q2 2019 | $18,892,000 | -3.0% | 499,000 | 0.0% | 0.57% | -14.3% |
| Q1 2019 | $19,471,000 | +232.1% | 499,000 | +81.5% | 0.67% | +157.7% |
| Q4 2018 | $5,863,000 | -46.1% | 275,000 | 0.0% | 0.26% | -35.0% |
| Q3 2018 | $10,887,000 | +3.6% | 275,000 | 0.0% | 0.40% | -8.3% |
| Q2 2018 | $10,508,000 | +29.5% | 275,000 | +1.9% | 0.44% | +14.7% |
| Q1 2018 | $8,114,000 | +15.4% | 270,000 | +20.0% | 0.38% | +3.5% |
| Q4 2017 | $7,031,000 | +11.6% | 225,000 | 0.0% | 0.37% | +2.8% |
| Q3 2017 | $6,302,000 | +46.4% | 225,000 | 0.0% | 0.36% | +33.2% |
| Q2 2017 | $4,304,000 | +12.3% | 225,000 | 0.0% | 0.27% | +5.5% |
| Q1 2017 | $3,834,000 | -6.7% | 225,000 | 0.0% | 0.25% | -4.9% |
| Q4 2016 | $4,111,000 | +2.6% | 225,000 | 0.0% | 0.27% | +9.0% |
| Q3 2016 | $4,007,000 | – | 225,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |